GuidelineAnnals of hematology2014
Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.
Guideline in Annals of hematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Guideline
- Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.British journal of haematology · 2016Trial
- Precision-guided therapy in dialysis-dependent classic hairy cell leukemia: a case report.Frontiers in oncology · 2026Article
- A Frail Hairy Cell Leukemia Patient Successfully Treated with Pegylated Interferon-α-2A.Journal of clinical medicine · 2022Article
- Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances.Current oncology reports · 2022Review
- Patients with relapsed/refractory hairy-cell leukemia.Cancer reports (Hoboken, N.J.) · 2022Article
- Advances in the Treatment of Hairy Cell Leukemia Variant.Current treatment options in oncology · 2022Review
- Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders.Frontiers in oncology · 2022Review
- Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.Therapeutic advances in hematology · 2022Review
- MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age.Cold Spring Harbor perspectives in medicine · 2021Review
- Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant.OncoTargets and therapy · 2021Review
- Biology and Treatment of Hairy Cell Leukemia.Current treatment options in oncology · 2020Review
- Difference of genomic copy numbers alterations between hairy cell leukemia-variant and classical hairy cell leukemia: a pilot retrospective study in Chinese.International journal of medical sciences · 2020Article
- A rare case of B-lymphoproliferative disorder with villous lymphocytes harboring t(8;14)(q24;q32) translocation.Frontiers of medicine · 2018Article
- Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment.American journal of hematology · 2017Article
- Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.Blood · 2017Article
- Long-term follow-up after purine analogue therapy in hairy cell leukaemia.Best practice & research. Clinical haematology · 2015Review
- Hairy cell leukemia: update and current therapeutic approach.Current opinion in hematology · 2015Review
- Current role of interferon in hairy cell leukemia therapy: a timely decision.Hematology, transfusion and cell therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 10 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hairy cell leukaemia (HCL) is a rare haematological malignancy, with approximately 175 new incident cases in France. Diagnosis is based on a careful examination of the blood smear and immunophenotyping of the tumour cells, with a panel of four markers being used specifically to screen for hairy cells (CD11c, CD25, CD103 and CD123). In 2011, the V600E mutation of the BRAF gene in exon 15 was identified in HCL; being present in HCL, it is absent in the variant form of HCL (HCL-v) and in splenic red pulp lymphoma (SRPL), two entities related to HCL. The management of patients with HCL has changed in recent years. A poorer response to purine nucleoside analogues (PNAs) is observed in patients with more marked leukocytosis, bulky splenomegaly, an unmutated immunoglobulin variable heavy chain (IgVH) gene profile, use of VH4-34 or with TP53 mutations. We present the recommendations of a group of 11 experts belonging to a number of French hospitals. This group met in November 2013 to examine the criteria for managing patients with HCL. The ideas and proposals of the group are based on a critical analysis of the recommendations already published in the literature and on an analysis of the practices of clinical haematology departments with experience in managing these patients. The first-line treatment uses purine analogues: cladribine or pentostatin. The role of BRAF inhibitors, whether or not combined with MEK inhibitors, is discussed. The panel of French experts proposed recommendations to manage patients with HCL, which can be used in a daily practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.